Aptevo Therapeutics Inc. (APVO) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US03835L7029
Aptevo Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -26.31 m USD |
| EBIT | -25.97 m USD |
| Net income | -25.97 m USD |
| Diluted EPS – continuing operations | -87.27 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head and neck squamous cell carcinoma, pancreatic, renal, ovarian, prostate, breast, cervical, colorectal, endometrial, and bladder cancers; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
More stocks
- NetBrands Corp. (NBND)
- Sadot Group Inc. (SDOT)
- Nature's Miracle Holding Inc. (NMHI)
- ENDONOVO THERAPEUTICS, INC. (ENDV)
- Trans American Aquaculture, Inc (GRPS)
- SOBR Safe, Inc. (SOBR)
- 1847 Holdings LLC (LBRA)
- Mobile Global Esports, Inc. (MGAM)
- TRAFALGAR INTERNATIONAL, INC. (GCAN)
- CNBX Pharmaceuticals Inc. (CNBX)
- Nauticus Robotics, Inc. (KITT)
- ProPhase Labs, Inc. (PRPH)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.